TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01468714
Drug: PF-04937319 / ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single 20 mg dose of PF-04937319 on day 1, multiple dose of ketoconazole 200 mg twice daily from day 3 to 7, single 20 mg dose of PF-04937319 on day 6
Study: NCT00728455
Drug: NNC 0070-0002-0349
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Study: NCT00728455
Drug: NNC 0070-0002-0349
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 2: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Study: NCT00728455
Drug: NNC 0070-0002-0349
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 3: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Study: NCT00728455
Drug: NNC 0070-0002-0349
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 4 for s.c. injection (6 subjects active, 2 subjects placebo)
Study: NCT00728455
Drug: NNC 0070-0002-0349
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 5 for s.c. injection (6 subjects active, 2 subjects placebo)
Study: NCT00656422
Drug: insulin Levemir
Normalized name: insulin detemir Injectable Solution [Levemir]
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The participant will receive an insulin dose of insulin Levemir at dinner subcutaneously according to a dosing algorithm.
Study: NCT00656422
Drug: insulin Lantus
Normalized name: insulin glargine Injectable Solution [Lantus]
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The participant will receive an insulin dose of the insulin Lantus at dinner subcutaneously according to a dosing algorithm.
Study: NCT01366417
Drug: ChloraPrep One-Step
Normalized name: ChloraPrep One-Step
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 ml applicator patient preoperative skin preparation
Study: NCT01366417
Drug: 70% isopropyl alcohol
Normalized name: GNP 70% Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curity Alcohol Prep Pads
Study: NCT03606785
Drug: Tranexamic Acid Injection
Normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The TA group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision
Study: NCT01750801
Drug: Propolis
Normalized name: propolis
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.. The criteria for selection stated that subjects should be from 18 to 60 years old, should present good health, a minimum of 20 teeth and not be pregnant or breastfeeding.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
Study: NCT01750801
Drug: chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
Study: NCT02105467
Drug: Grazoprevir 100mg / Elbasvir 50 mg FDC
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02105467
Drug: Placebo to Grazoprevir / Elbasvir 50 mg FDC
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03665740
Drug: Resveratrol
Normalized name: Resveratrol
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: resveratrol is an OTC supplement
Study: NCT03458078
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal injection of 10 mg hyperbaric bupivacaine 0.5% (2 ml) + 100γ morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 1 ml physiological saline.
Study: NCT03458078
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 100 mg MgSO4 (1 ml).
Study: NCT03458078
Drug: Midazolam 5 MG/ML Injection
Normalized name: midazolam 5 MG/ML Injection
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ Sufentanil (0.5ml) + 2mg Midazolam (0.4 + 0.6cc physiological saline (1 ml)).
Study: NCT00400374
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given Erlotinib (dose escalation from 50 mg, 75 mg, and 100 mg) once daily continuously for 6 months.
Study: NCT01068860
Drug: Canakinumab 150 mg
Normalized name: canakinumab 150 MG/ML
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single subcutaneous injection of Canakinumab 150 mg.
Study: NCT01068860
Drug: Placebo to Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single subcutaneous injection of Placebo to Canakinumab.
Study: NCT00648791
Drug: Finasteride Tablets 5 mg
Normalized name: finasteride Oral Tablet
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg, single dose fasting
Study: NCT02623062
Drug: Compound Sodium Alginate Oral Suspension sachet
Normalized name: sodium alginate / sodium bicarbonate Oral Suspension
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Contents of 2 sachets taken four times daily for 7 days
Study: NCT01371604
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin 200 mg tablets administered orally as a divided dose twice daily. Total daily dose to administered will be 1000 or 1200 mg based on body weight.
Study: NCT03374254
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tablet orally BID at 30 or 45 mg depending upon DLT profile
Study: NCT00317343
Drug: Bivalirudin (thrombin specific anticoagulant)
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous Coronary Intervention
Study: NCT00460603
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab 5 mg/kg every 2 weeks
Study: NCT00460603
Drug: AG-013726
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-013726 5 mg bid every 2 weeks
Study: NCT00460603
Drug: AG-013736 (axitinib)
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AG-013736 5 mg bid starting dose
Study: NCT01071915
Drug: Degarelix 240/80 mg
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
Study: NCT03492515
Drug: recombinant human thrombopoietin
Normalized name: Recombinant Human Thrombopoietin
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If platelet count \<30×10\^9/L and with haemorrhage or risk of bleeding,the patients began to receive subcutaneous injection of TPO with the dose of 300 Unit/kg qd,duration ≤14 days;If platelet count is between 30×10\^9/L and 50×10\^9/L, the dose will be 300 Unit/kg qod;If platlet count ≥100×109/L, stop this treatment;After delivery, if platelet count \<30×10\^9/L and with haemorrhage or risk of bleeding,subcutaneous injection of TPO with the dose of 300 Unit/kg qd or qod will be given at a duration ≤14 days;If platelet count is between 30×10\^9/L and 50×10\^9/L, the dose will be 300 Unit/kg qw;If platlet count ≥100×109/L, stop the treatment.
Study: NCT00402909
Drug: Nateglinide
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03374254
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m\^2 as IV infusion. Administered Q2W as part of mFOLFOX7 cocktail. Dose may be de-escalated to 70 mg/m\^2 if the standard dose of mFOLFOX7 is deemed too toxic per mTPI, based upon occurrence of DLTs.
Study: NCT01288807
Drug: Milnacipram
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titration to 200mg PO daily
Study: NCT03374254
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 mg/m\^2 as IV infusion. Administered Q2W as part of FOLFIRI cocktail. Dose may be de-escalated to 150 mg/m\^2 if the standard dose of FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
Study: NCT01641640
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir 400 mg tablet administered orally once daily
Study: NCT01641640
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT01641640
Drug: PEG
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
Study: NCT04666948
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin treatment
Study: NCT01113372
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75mg daily.
Study: NCT01681446
Drug: interferon-alpha (IFN-alpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: interferon-alpha is intramuscular injected 30 μg three times a week or 50 μg twice a week for 18 months
Study: NCT02308969
Drug: LSD
Normalized name: LSD
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100ug per os, single dose
Study: NCT02242812
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02242812
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02323412
Drug: Amoxicillin (Amoksicillintrihydrat)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin tablets 750 mg 1x3 for 100 days (oral intake).
Study: NCT00162981
Drug: Clobazam Low Dose
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 to 10 mg/day with doses in the morning and at bedtime; orally
Study: NCT00162981
Drug: Clobazam High Dose
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 to 40 mg/day with doses in the morning and at bedtime; orally
Study: NCT01778530
Drug: TRC105
Normalized name: IMMUNOGLOBULIN G1, ANTI-(HUMAN ENDOGLIN) (HUMAN-MUS MUSCULUS MONOCLONAL TRC105 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL TRC105 .KAPPA.-CHAIN, DIMER
DrugBank: Carotuximab (DB06322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion.
Study: NCT03785522
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with commercially available Tresiba® in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the study doctor and in accordance with the local label. The study doctor will determine the starting dose of Tresiba® as well as any dose adjustments thereafter.
Study: NCT01199939
Drug: Etravirine
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 400mg once daily orally for 48 weeks
Study: NCT01199939
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg once daily orally for 48 weeks
Study: NCT01199939
Drug: Darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 800mg once daily orally for 48 weeks
Study: NCT02544438
Drug: Astarabine (BST-236)
Normalized name: Cytarabine
DrugBank: Aspacytarabine (DB17226)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cohort # Astarabine Dose Number of Patients~1. 0.5 gr/m2 (0.3 age\>50) 3~2. 1.5 gr/m2(0.8age\>50) 3~3. 3.0 gr/m2(1.5 age\>50) 3~4. 4.5 gr/m2(2.3 age\>50) 6~5. 4.5 gr/m2 (no age limit) 3 up to 6~6. 6 gr/m2 (no age limit) 3 up to 6~Total number of patients: up to 24
Study: NCT01323517
Drug: Ipilimumab, Melphalan and Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isolated limb infusion ((ILI) with Melphalan and Dactinomycin- MSKCC operating room. Ipilimumab- IV administration in outpatient chemotherapy clinic. Induction therapy with Ipilimumab will start 1-3 weeks after ILI in the standard dose of 10mg/kg every 3 weeks for a total of 4 doses. Patients will then receive chronic therapy every 3 months. Patients will be followed every 3 months for 2 years.
Study: NCT00495391
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
Study: NCT00495391
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg (if \<75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Study: NCT02479620
Drug: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Following atherecomy-based revascularization, Investigators will be unblinded to assignment and will treat only patients assigned to the treatment arm with the Bullfrog delivery of dexamethasone.
Study: NCT03875508
Drug: Risankizumab
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab to be injected subcutaneously (SC)
Study: NCT03620708
Drug: Nicotine Replacement Therapy Sampling
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants are provided with a two-week sample of over-the-counter nicotine replacement therapy (i.e., nicotine lozenge and nicotine patch) and then provided with a written referral for tobacco dependence treatment.
Study: NCT01310842
Drug: Nicotine Patch Therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 weeks of nicotine patch therapy
Study: NCT00494637
Drug: sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isotonic sodium bicarbonate at 3 cc/kg for one hour followed by 2 cc kg/hr for 4 hours
Study: NCT00793871
Drug: Sunitinib Malate (SU011248)
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
Study: NCT00316511
Drug: Aroplatin
Normalized name: Aroplatin
DrugBank: Aroplatin (DB17319)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02712320
Drug: LMIS 50 mg
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection of 50 mg Leuprolide Mesylate
Study: NCT03596957
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: At baseline the tolvaptan dosing will start with daily morning and afternoon doses of 45 mg and 15 mg respectively, with weekly increases to 60 mg and 30 mg and then to 90 mg and 30 mg according to subject tolerability
Study: NCT02869243
Drug: hrBMP4
Normalized name: HRBMP4
DrugBank: Human Recombinant Bone Morphogenetic Protein 4 (DB17372)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo a resection or biopsy of the tumour, confirmation of viable malignant glioma tumour cells and intratumour/interstitial placement under neuronavigational guidance of 2 or 3 catheters.~Catheters will be placed during a second procedure a few days later based upon the patient's condition.~Patients will receive intra-tumour and interstitial CED of increasing amounts of hrBMP4 solutions (starting dose of 0.5 mg) and 1:70 gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) in a total of 44-66ml over up to 4-6 days. Gd-DTPA will be co-infused with BMP4 to determine the extent of intra-tumour and interstitial drug delivery. HrBMP4 will be delivered as a continuous infusion via the intracranial catheters.
Study: NCT03154983
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diagnosed with metastatic gastric cancer patients (including the esophagogastric junction adenocarcinoma), DS(docetaxel and Tegafur)and Mesylate apatinib 6 cycles, the specific amount of usage: DS Docetaxel 75mg/m2 D1 IV.drop 1H（one hour）, Tegafur(BSA\<1.25 40mg Po bid(twice a day), BSA \>=1.25-\<1.5 50mg Po bid, BSA \>=1.5 60mg Po bid, Q21d(21 days a cycle)); Mesylate Apatinib 500mg Po QD（once a day)） continuous use, until disease deterioration.
Study: NCT02996409
Drug: HVIGI
Normalized name: Hepatitis B Immune Globulin (Human)
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Volume Image-Guided Injection with a saline/lidocain solution
Study: NCT02996409
Drug: LVIGI
Normalized name: Levoglutamide
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control with injection of a saline/lidocain solution (low volume)
Study: NCT00637845
Drug: Esomeprazole Magnesium
Normalized name: Esomeprazole Magnesium
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg once daily
Study: NCT00637845
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg twice daily
Study: NCT01930162
Drug: HSC835
Normalized name: EXPANDED UMBILICAL CORD BLOOD PRODUCT HSC835
DrugBank: Spanlecortemlocel (DB17130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC).
Study: NCT04377204
Drug: marcaine bupivacaine
Normalized name: bupivacaine Injection [Marcaine]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.
Study: NCT04377204
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.
Study: NCT00210769
Drug: paliperidone ER Oros
Normalized name: paliperidone Extended Release Oral Tablet
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01051960
Drug: Ambrisentan
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ambrisentan 5mg or 10mg once daily
Study: NCT02094274
Drug: Salmeterol/fluticasone propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03139851
Drug: Pembrolizumab 100 MG in 4 ML Injection
Normalized name: pembrolizumab 100 MG in 4 ML Injection
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion every 3 weeks. Pembrolizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study: NCT01253902
Drug: bimatoprost ophthalmic solution 0.01%
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One drop of bimatoprost ophthalmic solution 0.01% administered to affected eye(s), once daily in the evening for 12 weeks.
Study: NCT01253902
Drug: travoprost ophthalmic solution 0.004%
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One drop of travoprost ophthalmic solution 0.004% administered to affected eye(s), once daily in the evening for 12 weeks.